Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:9953
Name acute biphenotypic leukemia
Definition An acute leukemia that is characterized by the occurrence of more than one type of leukemia at the same time resulting from either the occurrence of blasts which coexpress myeloid and T or B lineage antigens or concurrent B and T lineage antigens.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute biphenotypic leukemia

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
NRAS Q61R Trametinib acute biphenotypic leukemia no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02091245 Phase I Selinexor Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML Active, not recruiting USA 0
NCT03326921 Phase I Fludarabine HA-1 TCR T cells HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Suspended USA 0
NCT04501614 Phase Ib/II Ponatinib A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | AUS 8
NCT04827745 Phase II Blinatumomab Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL Active, not recruiting USA 0
NCT04872478 Phase I MRX-2843 Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL Recruiting USA 0
NCT04964518 Phase I APG-2575 + Azacitidine A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) Recruiting USA | AUS 0
NCT05038644 Phase I XmAb18968 XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia Recruiting USA 0
NCT05146739 Phase I Cytarabine + Fludarabine + Uproleselan Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane Recruiting USA 0
NCT05292664 Phase I Azacitidine + Cytarabine + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax Calaspargase pegol-mknl + Cytarabine + Dexamethasone + Dexrazoxane + Doxorubicin + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax + Vincristine Sulfate Azacitidine + Venetoclax Venetoclax Basket Trial for High Risk Hematologic Malignancies Recruiting USA 0
NCT05326516 Phase I Revumenib A Study of SNDX-5613 in Combination With Chemotherapy in Participants With R/R Acute Leukemia Active, not recruiting USA | CAN 0
NCT05327894 Phase III Blinatumomab Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia (Interfant-21) Recruiting NLD | ITA | FRA | DEU | BEL | AUT | AUS 11
NCT05360160 Phase Ib/II Decitabine and Cedazuridine Revumenib Venetoclax A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) Recruiting USA 0
NCT05476770 Phase I Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Tagraxofusp-erzs + Vincristine Sulfate Azacitidine + Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Fludarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Recruiting USA | AUS 0
NCT05761171 Phase II Cytarabine + Fludarabine Pegaspargase + Prednisone + Vincristine Sulfate Calaspargase pegol-mknl + Prednisone + Vincristine Sulfate Revumenib Cytarabine + Hydrocortisone + Methotrexate Pegaspargase + Prednisolone + Vincristine Sulfate Calaspargase pegol-mknl + Prednisolone + Vincristine Sulfate A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Recruiting USA 0
NCT05848687 Phase Ib/II Bortezomib Dexamethasone Blinatumomab Vorinostat Mercaptopurine Pegaspargase Methotrexate Ziftomenib Mitoxantrone TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II Recruiting USA 0
NCT05918692 Phase I BMF-500 A Phase 1, Study of BMF-500 in Adults With Acute Leukemia Recruiting USA 0
NCT06390319 Phase II Cyclophosphamide + Cytarabine + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Vincristine Sulfate Bortezomib + Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Vincristine Sulfate Bortezomib + Calaspargase pegol-mknl + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Vincristine Sulfate Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Venetoclax + Vincristine Sulfate Calaspargase pegol-mknl + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Venetoclax + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Vincristine Sulfate Thioguanine Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Vincristine Sulfate Calaspargase pegol-mknl + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Vincristine Sulfate Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) Not yet recruiting USA 0
NCT06397027 Phase I Azacitidine + Venetoclax + Ziftomenib A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias Not yet recruiting USA 0